












844Comparison of Tacrolimus and Sirolimus (Tac/Sir)
versus Tacrolimus, Sirolimus, and Mini-Methotrexate
(Tac/Sir/MTX) as Acute Graft-versus-Host Disease
Prophylaxis after Reduced-Intensity Conditioning
Allogeneic Peripheral Blood Stem Cell Transplantation
Vincent T. Ho,1 Julie Aldridge,2 Haesook T. Kim,2 Corey Cutler,1 John Koreth,1
Philippe Armand,1 Joseph H. Antin,1 Robert J. Soiffer,1 Edwin P. Alyea1Previous studies have shown that adding sirolimus to a tacrolimus/mini-methotrexate regimen (Tac/Sir/MTX)
as graft-versus-host disease (GVHD) prophylaxis produces low rates of acute GVHD (aGVHD) after re-
duced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). To assess whether posttrans-
plantation methotrexate MTX can be safely eliminated altogether, we conducted a prospective clinical trial
testing the combination of Tand Sir alone (tac/sir) as GVHD prophylaxis after RIC SCT frommatched related
donors.We compared the results with patients who received (Tac/Sir/MTX) as GVHD prophylaxis after RIC
SCT from matched related donors in a previous prospective study. Patients in both groups received i.v. flu-
darabine (Flu) 30 mg/m2/day and i.v. busulfan (Bu) 0.8 mg/kg/day on days -5 to -2 as conditioning, followed by
transplantation of unmanipulated filgrastim-mobilized peripheral blood stem cells (PBSCS). After transplan-
tation, patients in both groups received Tac and Sir orally starting on day -3, with doses adjusted to achieve
trough serum levels of 5 to 10 ng/mL and 3 to 12 ng/mL, respectively. The patients in the Tac/Sir/MTX group
also receivedmini-MTX therapy (5 mg/m2 i.v.) on days11,13, and16. Filgrastim 5 mg/kg/day s.c. was started
on day 11 and continued until neutrophil engraftment. Twenty-nine patients received the Tac/Sir regimen,
and 46 patients received the Tac/Sir/MTX regimen. The 2 groups were balanced in terms of age, sex, and
disease characteristics. Engraftment was brisk and donor chimerism after transplantation robust in both
groups. The cumulative incidence of grade II-IV aGVHD was similar in the 2 groups (17% for Tac/Sir versus
11% for Tac/Sir/MTX; P5.46). There also were no differences between the 2 groups in cumulative incidence
of extensive chronic GVHD (cGVHD), treatment-related mortality (TRM), disease relapse, or survival. The
Tac/Sir combination for GVHDprophylaxis is well tolerated and associated with a low incidence of aGVHD in
matched related donor RIC SCT. The omission of mini-MTX from the Tac/Sir GVHD prophylaxis regimen
appears to have no adverse effect on the development of aGVHD.
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6/j.bbmt.2009.03.017cell transplantation (SCT), acute graft-versus-host
disease (aGVHD) remains a significant cause ofmorbid-
ity and mortality. Various immunosuppressive drug
combinations have been used as GVHD prophylaxis in
RIC, but an optimal regimen has not been defined.
Commonly used combinations include a calcineurin-in-
hibitor with low-dose methotrexate (MTX), mycophe-
nolate mofetil (MMF) [1,2], and the addition of in vivo
T cell depletion with alemtuzumab or antithymocyte
globulin (ATG) [3,4]. The latter are associated with
a low incidence of aGVHD; however, the associated
loss of the graft-versus-malignancy effect can be prob-
lematic, often necessitating T cell add-back or donor
lymphocyte infusion (DLI). These issues underscore
the fact that in RIC SCT, where the graft-versus-
Biol Blood Marrow Transplant 15:844-850, 2009 845Tacrolimus and Sirolimus as GVHD Prophylaxis for R/C SCTmalignancy effect is tantamount, an effective GVHD
prophylaxis regimenmust achieveGVHDcontrolwith-
out impairing immune reconstitution and the graft-
versus- malignancy effect.
Sirolimus (Sir), a macrocyclic lactone immuno-
suppressive agent similar in structure to tacrolimus
(Tac), is increasingly used in GVHD prophylaxis reg-
imens after allogeneic SCT. Unlike Tac or cyclospor-
ine (CsA), Sir is an inhibitor of the mammalian target
of rapamycin (mTOR). It binds with FKBP12 and the
raptor/rictor proteins [5]. This sirolimus-FKBP12-
mTORcomplex inhibits the pathways required for sig-
nal transduction and cell cycle progression, resulting in
T cell suppression and impaired dendritic cell function.
In experimentalmodels, Sir does not impede the expan-
sion of CD41CD251FoxP3 regulatory T cells, and, as
such, it has been suggested to preserve the graft-versus-
leukemia (GVL) effect [6-8].
Several previous studies have shown that the com-
bination of Tac and Sir (Tac/Sir), with or without the
addition of low-dose MTX, is effective in preventing
aGVHD after myeloablative hematopoietic SCT. In
these studies, which used high-dose cyclophospha-
mide (Cy) and total body irradiation (TBI; 1400
cGy) as conditioning, both Tac/Sir and Tac/Sir/
MTX were associated with grade II-IV aGVHD rates
of 19% for matched related donor transplantation and
28% to 30% for mismatched related or matched unre-
lated donor transplantation [9,10]. The experience
with tac/sir combinations as GVHD prophylaxis in
RIC SCT is more limited. We recently reported that
the Tac/Sir/MTX regimen resulted in a low incidence
of grade II-IV aGVHD after RIC allogeneic SCT
from matched related and unrelated donors in patients
with hematologic malignancies [11].
To explore whether MTX can be safely eliminated
without compromising GVHD outcomes, we con-
ducted a prospective clinical trial testing the Tac/Sir
combination as GVHD prophylaxis after RIC SCT
from matched related donors. We report the results
of 29 patients who underwent transplantation on this
trial and compare them with the results for a group
of 46 patients who received Tac/Sir/MTX after RIC
SCT from matched related donors in an earlier pro-
spective study [11]. We demonstrate that the Tac/Sir
combination without MTX is sufficient for aGVHD
prevention in patients undergoing RIC allogeneic
SCT from matched related donors.PATIENTS AND METHODS
All patients with a hematologic malignancy who
had a matched related donor and was deemed an
appropriate candidate for RIC allogeneic SCT were
eligible for the 2 prospective clinical trials. Enrollment
for the Tac/Sir/MTX trial occurred between Septem-
ber 2002 and December 2004, and enrollment for theTac/Sir trial occurred between January 2006 and Oc-
tober 2007. Transplantation eligibility requirements
included an Eastern Cooperative Oncology Group
performance status of 0 to 2, the absence of uncon-
trolled infection at the time of study entry, a left ven-
tricular ejection fraction (LVEF) . 30%, and normal
or near-normal kidney and liver function parameters.
All patients were considered to have some relative con-
traindications to myeloablative transplantation, such
as previous autologous SCT, age . 50 years, signifi-
cant medical comorbidity, or organ dysfunction.
Low-risk disease was defined as acute leukemia in first
complete remission (CR1), de novo early-stage myelo-
dysplastic syndrome (MDS) with refractory anemia
(RA) or RA with ringed sideroblasts (RARS), and first
chronic-phase chronic myelogenous leukemia (CML).
All others were considered high risk. Dana-Farber/
Harvard Cancer Center’s Human Subjects Protection
Committee approved both clinical trial protocols.
Written informed consent was obtained from all
patients before transplantation.
All of the related donors in the 2 trials were siblings
of the patient and were HLA-matched at -A, -B, and
-DRB1 loci at the allele level. HLA typing was per-
formed with sequence-specific oligonucleotide probes
(SSOP). All patients received filgrastim-mobilized pe-
ripheral blood stem cells (PBSCs). Donors were mobi-
lized with filgrastim at 10 mg/kg/day for 5 days. Stem
cell collection was initiated on day 5 of filgrastim ther-
apy and continued until a sufficient number of CD341
cells were obtained. Target cell dose was 5.0  106
CD341 cells/kg. The first day of stem cell infusion
was defined as day 0.
In both trials, the conditioning regimen consisted of
i.v. fludarabine (Flu; 30mg/m2/day ondays25,24,23,
and22) and i.v. busulfan (Bu; 0.8mg/kg/day on days -5,
24,23, and22).Tac 0.05mg/kg/day (in 2dailydivided
doses) was given orally starting on day23, with a target
serum concentration of 5 to 10 ng/mL. Sir was adminis-
tered as a 12-mgoral loadingdose onday -3, followedby
a 4-mg daily dose, adjusted to maintain a target serum
concentration of 3 to 12 ng/mL as determined by
high-pressure liquid chromatography (HPLC). In the
Tac/Sir/MTX trial,mini-MTX (5mg/m2 i.v.)was given
on days11,13, and16. In the Tac/Sir trial, the mini-
MTXwas omitted. All patients received unmanipulated
PBSCs. Filgrastim was administered at 5 mg/kg/day be-
ginning on day 11 and was continued until neutrophil
engraftment. All patients received oral acyclovir as pro-
phylaxis againstherpes virus infections and sulfamethox-
azole/trimethoprim or atovoquone as prophylaxis
against Pneumocystis jurivecii. No systemic prophylactic
antifungal therapy was given. Patients were monitored
for peripheral blood cytomegalovirus (CMV) reactiva-
tion by DNA hybrid capture during the first 100 days
posttransplantation, and preemptive therapy with gan-
ciclovir or valganciclovir was started if CMV DNA .
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ing to the consensus grading scale [12]. Tapering of
Tac and Sir doses was encouraged after day 164,
with the goal of discontinuing immunosuppression
therapy by approximately 6 months posttransplanta-
tion in the absence ofGVHD. If a patient developed ev-
idence of recurrent or progressive disease, then rapid
withdrawal/taper of Tac or Sir was allowed at the treat-
ing physician’s discretion. No preemptive or prophy-
lactic DLI were planned as part of either protocol.
Chimerism Analysis
Unfractionated donor chimerism was assessed
from bone marrow aspirates and/or peripheral blood
at approximately day 130 to 145 and again at 3 to 4
months posttransplantation. Genotypes of the donor
and recipient were determined using DNA extracted
from pretransplantation samples. Nine short tandem
repeat loci were typed using the ABI Profiler Plus
Kit and the ABI 310Genetic Analyzer (Applied Biosys-
tems, Foster City, CA) to resolve alleles. ‘‘Informative’’
alleles that were present only in the donor or recipient
were used in the chimerism calculations.
Statistical Analysis
The 2 clinical trials of Tac/Sir and Tac/Sir/MTX
were single-arm prospective phase II trials, with the
primary objective of assessing the rate of grade II-IV
aGVHD. The Tac/Sir trial was a single-stage design
with an accrual goal of 30 patients and an alternative
hypothesis of a 15% rate of grade II-IV aGVHD. An
early-stopping rule was imposed to stop the study early
in the event of excessive grade III-IV aGVHD. This
trial reached full accrual; however, data for 1 patient
were unavailable at the time of analysis and thus are ex-
cluded from this report.
Descriptive statistics was provided for patient
baseline characteristics. The 2-sided Fisher’s exact
test was used to compare categorical variables, and
the 2-sided Wilcoxon-rank-sum test was used to com-
pare continuous variables.
Cumulative incidence curves for aGVHD and
chronicGVHD (cGVHD)were constructed reflecting
early death and death or relapse, respectively, as a com-
peting risk. In constructing the cumulative incidence
curves for aGVHD, patients who suffered early disease
progression/relapse and subsequently developed
aGVHD in the setting of rapid termination of Tac
and Sir were categorized as having relapsed, not
aGVHD. Cumulative incidence curves for treatmet-
related death and relapse with or without death were
constructed reflecting time to relapse and time to
treatment-related death as competing risks. The dif-
ference between cumulative incidence curves in the
presence of a competing risk was tested using the
method of Gray [13]. Time to relapse and time totreatment-related death were measured from the date
of stem cell infusion. Patients who were alive without
relapse were censored at the date last seen alive. Over-
all survival (OS) and progression-free survival (PFS)
were calculated using the Kaplan-Meier method. OS
was defined as the time from stem cell infusion to death
from any cause; PFS, as the time from stem cell infu-
sion to relapse, disease progression, or death from
any cause. The log-rank test was used for comparing
Kaplan-Meier curves. Prognostic factors for OS and
PFS were examined in Cox proportional hazard
models, and aGVHD, cGVHD, relapse, and treat-
ment-related death were examined in competing-risks
regression models [14].RESULTS
Patient Characteristics
Table 1 summarizes the characteristics of the 29
patients in the Tac/Sir trial and the 45 patients in the
Tac/Sir/MTX trial. The 2 groups were well balanced
in terms of age, sex, donor–recipient sex mismatch,
previous autologous SCT, and disease risk. Median
patient age was 53 years (range, 29 to 64 years) for
the Tac/Sir group and 55 years (range, 20 to 69 years)
for the Tac/Sir/MTX group. Approximately 35% of
patients in both groups had undergone previous mye-
loablative autologous or allogeneic SCT. The median
follow-up for survivors was 1.84 years for the Tac/Sir
group and 3.26 years for the Tac/Sir/MTX group.
Stem Cell Product and Engraftment
The median number of CD341 cells infused was
8.0  106 cells/kg (range, 2.6 to 38  106) for the
Tac/Sir group and 8.5  106 cells/kg (range, 1.8 to 9
 106) for the Tac/Sir/MTX group (P5 .73). No cases
of primary graft failure were noted in either group. In
the Tac/Sir group, only 6 of 29 patients (21%) devel-
oped neutropenia (ie, absolute neutrophil count \
500 cells/mL) or significant thrombocytopenia (ie,
platelets\ 20,000 cells/mL). In contrast, in the Tac/
Sir/MTX group, 52% developed neutropenia (P 5
.008) and 41% developed thrombocytopenia (P 5
.047). In those patients whose blood counts hit a nadir,
there was no difference in time to neutrophil or platelet
engraftment between the 2 groups (median time to
neutrophil engraftment: 13 days for Tac/Sir vs 13
days for Tac/Sir/MTX [P5 .84]; median time to plate-
let engraftment: 19 days vs 20 days, respectively [P 5
.85]).
Donor-derived hematopoiesis was assessed on to-
tal nucleated cells from the peripheral blood between
days 1 25 and 1 40, and again approximately 100
days posttransplantation. In the Tac/Sir group, me-
dian donor chimerism at approximately 1 month post-
transplantation was 94% (range, 32% to 99%), with
Table 1. Patient Characteristics
Tac/Sir Tac/Sir/Mtx
n % n % P value
Total 29 100 46 100
Age .80
$ 50 years 20 69 33 72
< 50 years 9 31 13 28
Median (range), years 53 (29 to 64) 55 (20 to 69)
Sex .25
Male 17 59 33 72
Female 12 41 13 28
Patient–donor sex matching .64
MF 11 38 18 39
MM 6 21 15 32
FF 7 24 6 13
FM 5 17 7 15
Previous transplantation .98
Yes 10 34 16 35
No 19 66 30 65
Diagnosis –
Acute myelogenous leukemia 6 21 14 30




3 10 7 15
CML 3 10 2 4
Hodgkin disease 5 17 4 44
MDS 1 3 8 17
Multiple myeloma/plasma
cell disorder
2 7 2 4
Myeloproliferative disorder – – 1 2
Non-Hodgkin lymphoma 9 31 7 15
Risk status .37
High risk 12 41 11 24
Low risk* 17 59 35 76
*M indicates male; F, female; CML, chronic myelogenous leukemia; MDS,
meloproliferative disease; Tac, tacrolimus; sir, sirolimus. Low risk was
defined as acute leukemia in CR1, de novo MDS-RA or RARS, or first
chronic- phase CML. All others were considered high risk.
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Figure 1. Cumulative incidence of grade II-IV acute GVHD with early
death as a competing risk.was 95% (range, 11% to 100%), with 78% of patients
achieving $ 90% donor-derived hematopoiesis. Simi-
larly, in the Tac/Sir/MTX group, median donor chi-
merism at approximately 30 days posttransplantation
was 92% (range, 11% to 100%), with 61% of patients
achieving $ 90% donor-derived hematopoiesis. The
difference between groups in the percentage of pa-
tients achieving $ 90% donor chimerism at 1 month
was not statistically significant (71% vs 61%; P
5.44). Because 35% of the chimerism data at around
day 1100 was missing for patients in the Tac/Sir/
MTX group, median donor chimerism was not calcu-
lated for this time point.Graft-versus-Host Disease
The cumulative incidence of grade II-IV aGVHD
was similar in the Tac/Sir and Tac/Sir/MTX groups
(17.2% vs 10.9%; P 5 .46) (Figure 1). One case of
grade IV aGVHD occurred in the Tac/Sir/MTX
group. No aGVHD–related deaths occurred in either
group. The cumulative incidence of cGVHD was
higher in the Tac/Sir group (74% vs 43%; P 5 .02);
however, this difference resulted mainly from a higher
incidence of limited cGVHD—the cumulative inci-
dence of extensive cGVHDwas similar in the 2 groups
(38% for Tac/Sir and 30% for Tac/Sir/MTX; P5 .47)
(Figure 2). The newNational Institutes of Health con-
sensus scoring definitions for cGVHD were not yet
available during the 2 trials.Relapse, Treatment-Related Mortality (TRM),
and Survival
OS at day1100 was 97% in the Tac/Sir group and
98% in the Tac/Sir/MTX group. No cases of hepatic





















Figure 2. Cumulative incidence of extensive chronic GVHD with
death/relapse as a competing risk.






















































848 Biol Blood Marrow Transplant 15:844-850, 2009V. T. Ho et al.Transplantation-associated thrombotic microangiop-
athy was observed in 2 patients (1 patient in each
group); both cases resolved with discontinuation of ta-
crolimus. The cumulative incidence of disease relapse
andTRMwere similar in the 2 groups (Figure 3).With
a median follow-up time of 1.84 years for the Tac/Sir
group and 3.26 years for the Tac/Sir/MTX group,
there was a trend toward better OS for the Tac/Sir
group (OS at 2 years: 76% vs 47%; P 5 .07)
(Figure 4A); however, this might result from the
shorter follow-up time in that group. PFS estimates
at 2 years were similar in the 2 groups (48% for Tac/
Sir and 26% for Tac/Sir/MTX; P 5 .58) (Figure 4B).
Factors Associated with Outcome and Toxicity
Cox regression analysis was performed to identify
factors associated with grade II-IV aGVHD, extensive
cGVHD, TRM, OS, and PFS. Factors analyzed in-
cluded age, patient–donor sex mismatch, Tac/Sir ver-
sus Tac/Sir/MTX, previous autologous SCT, and
disease risk at time of transplantation. In competing-
risk regression models for aGVHD and extensive
cGVHD, reflecting early disease progression/relapse
as a competing risk, omission of mini-methotrexate,
age $ 50, previous SCT, high disease risk, and do-
nor–recipient sex mismatch were not associated with
an increased risk of aGVHD or extensive cGVHD.
Omission of mini-MTX was not associated with any
difference in the relative risk for TRM, OS, or PFS.0.0
0.2
Months
0 6 12 18 24 30
Tac/Sir/MTX
Figure 4. OS (A) and PFS (B).DISCUSSION
We have previously shown that the potent immu-
nosuppressive agent Sir, combined with Tac and
low-dose MTX results in low rates of grade II-IV
aGVHD for both related and unrelated donor RICSCT [11]. In the current study, we have demonstrated
that the combination of Tac and Sir alone, omitting
low-dose MTX, is similarly effective in preventing
aGVHD. After adjusting for relapsed patients who
had aGVHD induced by rapid withdrawal of immuno-
suppressive therapy, the cumulative incidence of grade
II-IV aGVHD was 17% for those patients receiving
Tac/Sir as GVHD prophylaxis. This finding is in ac-
cordance with previously published results using this
same prophylaxis regimen in myeloablative matched
related donor PBSC transplantation, with a 10% inci-
dence of grade II-IV aGVHD and minimal TRM [15].
A multicenter randomized trial testing the combina-
tion of Tac and Sir versus Tac and MTX in matched
sibling donormyeloablative transplantation is ongoing
through the BMT Clinical Trials Network.
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the elimination of posttransplantation MTX from
the Tac/Sir combination may have some potential
benefits. The lack of MTX may have accounted for
the significantly lower incidences of neutropenia and
significant thrombocytopenia in the Tac/Sir group
compared with the Tac/Sir/MTX group (21% vs
52% and 21% vs 41%, respectively). The elimination
of methotrexate also may provide cost savings and
enhance patient convenience, because it obviates the
need for multiple clinic infusion visits during the first
week after stem cell infusion.
The incidence of aGVHDnoted in this study com-
pares favorably with that associated with other phar-
macologic strategies for GVHD prophylaxis after
RIC SCT. In RIC related donor SCT, the incidence
of grade II-IV aGVHD ranges from 16% to 47%
with Tac or CsA and MMF [16,17] and from 12% to
36% with Tac or CsA and MTX [18]. Incorporation
of alemtuzumab or antithymocyte globulin (ATG) in
GVHD prophylaxis is associated with a low incidence
of aGVHD and cGVHD after RIC SCT; however,
these in vivo T cell–depleting approaches are associ-
ated with an increased risk of infection and disease
relapse, often requiring donor lymphocyte infusion
to restore the GVL effect [4,19].
Along with its immunosuppressive properties, Sir
may have additional benefits in allogeneic SCT be-
yond GVHD prevention. Along with other mTOR in-
hibitors, sirolimus has been shown to have direct
anticancer activity in several hematologic malignancies
[20]. This anticancer activity appears to be mediated
through inhibition of themTORpathway and involves
blockading immature cells in the G0/G1 phase of the
cell cycle. Although whether the doses used to prevent
aGVHD are sufficient to mediate anticancer activity is
unclear, results of a recent retrospective study on pa-
tients with lymphoma undergoing RIC SCT with
Bu/Flu conditioning demonstrated that those who un-
derwent transplantation using Tac/Sir-based GVHD
prophylaxis had better disease-free survival than those
receiving non–sirolimus-containing GVHD prophy-
laxis [21]. Preliminary results incorporating Sir into
a RIC regimen in a cohort of patients with high-risk
leukemia also suggested improved disease control after
transplantation [22]. Larger series are needed to assess
the impact of Sir on disease control. Interestingly, re-
cent data suggest that the combination of mTOR in-
hibitors with MTX can provide a synergistic effect
against acute lymphoblastic leukemia (ALL) in cell
lines and animal models [23].
As is true in many single-institution nonrandom-
ized phase II studies, our data are limited by the fact
that the study populations for the 2 trials are small,
and thus there is insufficient power to detect small dif-
ferences in GVHD outcomes. Furthermore, the Tac/
Sir/MTX trial was conducted a few years before theTac/Sir trial, which could have affected the TRM
comparisons, because supportive care and antifungal
therapy have improved in recent years (although this
difference should not influence the development of
GVHD). Definitive confirmation of aGVHD inci-
dence with Tac/Sir versus Tac/Sir/MTX will require
a prospective randomized phase III trial.
In summary, ourfindings demonstrate that the com-
bination of Tac and Sir alone is associated with good
aGVHD control and little toxicity after RIC SCT
from matched sibling donors. The use of low-dose i.v.
Bu with Sir in this RIC setting does not appear to in-
crease the risk of hepatic veno-occlusive disease or
thrombotic microangiopathy. Although the incidence
of cGVHD remains high, long-term survival outcomes
are encouraging, suggesting preservation of the graft-
versus-malignancy effect. Sir-containing GVHD pro-
phylaxis regimens in RIC SCT merit further investiga-
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